AVALO THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
AVALO THERAPEUTICS, INC. (AVTX) reported Share-based Payment Arrangement, Expense of $5.31 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- AVALO THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $5.31M, a 95.22% increase year-over-year.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $3.58M, a 10.31% increase year-over-year.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $4.51M, a 55.23% increase year-over-year.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $3.15M, a 70.62% increase year-over-year.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $13.62M, a 132.76% increase from fiscal 2024.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $5.85M, a 68.40% increase from fiscal 2023.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $3.48M, a 54.00% decline from fiscal 2022.
- AVALO THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $7.55M, a 7.56% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $5.31M 10-Q · filed 2026-08-06 | $8.88M 10-Q · filed 2026-08-06 | $13.39M derived: sum of 3 quarters · filed 2026-08-06 | $16.54M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $3.58M 10-Q · filed 2026-05-13 | $8.08M derived: sum of 2 quarters · filed 2026-05-13 | $11.24M derived: sum of 3 quarters · filed 2026-05-13 | $13.95M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $4.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $7.66M derived: sum of 2 quarters · filed 2026-03-23 | $10.38M derived: sum of 3 quarters · filed 2026-08-06 | $13.62M 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | $3.15M 10-Q · filed 2025-11-06 | $5.87M derived: sum of 2 quarters · filed 2026-08-06 | $9.11M 10-Q · filed 2025-11-06 | $12.02M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $2.72M 10-Q · filed 2026-08-06 | $5.96M 10-Q · filed 2026-08-06 | $8.86M derived: sum of 3 quarters · filed 2026-08-06 | $10.71M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $3.24M 10-Q · filed 2026-05-13 | $6.14M derived: sum of 2 quarters · filed 2026-05-13 | $7.99M derived: sum of 3 quarters · filed 2026-05-13 | $8.46M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $4.75M derived: sum of 2 quarters · filed 2026-03-23 | $5.22M derived: sum of 3 quarters · filed 2026-03-23 | $5.85M 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $1.85M 10-Q · filed 2025-11-06 | $2.32M derived: sum of 2 quarters · filed 2025-11-06 | $2.95M 10-Q · filed 2025-11-06 | $3.72M derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $471.00K 10-Q · filed 2025-08-07 | $1.10M 10-Q · filed 2025-08-07 | $1.87M derived: sum of 3 quarters · filed 2025-08-07 | $2.83M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $629.00K 10-Q · filed 2025-05-12 | $1.40M derived: sum of 2 quarters · filed 2025-05-12 | $2.36M derived: sum of 3 quarters · filed 2025-05-12 | $3.25M derived: sum of 4 quarters · filed 2025-05-12 | ||||
| 2023-12-31 | $774.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.73M derived: sum of 2 quarters · filed 2025-03-20 | $2.62M derived: sum of 3 quarters · filed 2025-03-20 | $3.48M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | $953.00K 10-Q · filed 2024-11-07 | $1.85M derived: sum of 2 quarters · filed 2024-11-07 | $2.70M 10-Q · filed 2024-11-07 | $3.54M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $893.00K 10-Q · filed 2024-08-12 | $1.75M 10-Q · filed 2024-08-12 | $2.59M derived: sum of 3 quarters · filed 2024-08-12 | $3.32M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $855.00K 10-Q/A · filed 2024-07-11 | $1.70M derived: sum of 2 quarters · filed 2024-07-11 | $2.43M derived: sum of 3 quarters · filed 2024-07-11 | $3.10M derived: sum of 4 quarters · filed 2024-07-11 | ||||
| 2022-12-31 | $843.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.57M derived: sum of 2 quarters · filed 2024-03-29 | $2.24M derived: sum of 3 quarters · filed 2024-03-29 | $7.55M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $731.00K 10-Q · filed 2023-11-09 | $1.40M derived: sum of 2 quarters · filed 2023-11-09 | $6.71M 10-Q · filed 2023-11-09 | $8.60M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | $669.00K 10-Q · filed 2023-08-03 | $5.98M 10-Q · filed 2023-08-03 | $7.87M derived: sum of 3 quarters · filed 2023-08-03 | $9.63M derived: sum of 4 quarters · filed 2023-08-03 | ||||
| 2022-03-31 | $5.31M 10-Q · filed 2023-05-04 | $7.20M derived: sum of 2 quarters · filed 2023-05-04 | $8.96M derived: sum of 3 quarters · filed 2023-05-04 | $12.04M derived: sum of 4 quarters · filed 2023-05-04 | ||||
| 2021-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $3.65M derived: sum of 2 quarters · filed 2023-03-29 | $6.72M derived: sum of 3 quarters · filed 2023-03-29 | $8.17M 10-K · filed 2023-03-29 | ||||
| 2021-09-30 | $1.76M 10-Q · filed 2022-11-07 | $4.83M derived: sum of 2 quarters · filed 2022-11-07 | $6.28M 10-Q · filed 2022-11-07 | $7.72M derived: sum of 4 quarters · filed 2022-11-07 | ||||
| 2021-06-30 | $3.07M 10-Q · filed 2022-08-04 | $4.52M 10-Q · filed 2022-08-04 | $5.96M derived: sum of 3 quarters · filed 2022-08-04 | $7.41M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $1.45M 10-Q · filed 2022-05-05 | $2.88M derived: sum of 2 quarters · filed 2022-05-05 | $4.33M derived: sum of 3 quarters · filed 2022-05-05 | $7.12M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $2.88M derived: sum of 2 quarters · filed 2022-03-02 | $5.67M derived: sum of 3 quarters · filed 2022-03-02 | $6.79M 10-K · filed 2022-03-02 | $6.79M 10-K · filed 2021-03-08 | |||
| 2020-09-30 | $1.45M 10-Q · filed 2021-11-09 | $1.45M 10-Q · filed 2020-11-09 | $4.23M derived: sum of 2 quarters · filed 2021-11-09 | $5.35M 10-Q · filed 2021-11-09 | $5.35M 10-Q · filed 2020-11-09 | $5.87M derived: sum of 4 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $2.79M 10-Q · filed 2021-08-02 | $2.79M 10-Q · filed 2020-08-06 | $3.90M 10-Q · filed 2021-08-02 | $3.90M 10-Q · filed 2020-08-06 | $4.42M derived: sum of 3 quarters · filed 2021-08-02 | $5.24M derived: sum of 4 quarters · filed 2021-08-02 | ||
| 2020-03-31 | $1.12M 10-Q · filed 2021-05-13 | $1.12M 10-Q · filed 2020-05-07 | $1.64M derived: sum of 2 quarters · filed 2021-05-13 | $2.46M derived: sum of 3 quarters · filed 2021-05-13 | $2.98M derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2019-12-31 | $520.60K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $1.34M derived: sum of 2 quarters · filed 2021-03-08 | $1.87M derived: sum of 3 quarters · filed 2021-03-08 | $2.46M 10-K · filed 2021-03-08 | ||||
| 2019-09-30 | $818.79K 10-Q · filed 2020-11-09 | $1.35M derived: sum of 2 quarters · filed 2020-11-09 | $1.94M 10-Q · filed 2020-11-09 | $2.58M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $526.71K 10-Q · filed 2020-08-06 | $1.12M 10-Q · filed 2020-08-06 | $1.76M derived: sum of 3 quarters · filed 2020-08-06 | $2.70M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $596.69K 10-Q · filed 2020-05-07 | $1.23M derived: sum of 2 quarters · filed 2020-05-07 | $2.18M derived: sum of 3 quarters · filed 2020-05-07 | $2.78M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $634.68K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $1.58M derived: sum of 2 quarters · filed 2020-03-11 | $2.19M derived: sum of 3 quarters · filed 2020-03-11 | $2.43M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | $945.13K 10-Q · filed 2019-11-14 | $1.55M derived: sum of 2 quarters · filed 2019-11-14 | $1.80M 10-Q · filed 2019-11-14 | $2.10M derived: sum of 4 quarters · filed 2019-11-14 | ||||
| 2018-06-30 | $608.43K 10-Q · filed 2019-08-08 | $851.25K 10-Q · filed 2019-08-08 | $1.16M derived: sum of 3 quarters · filed 2019-08-08 | $1.42M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $242.82K 10-Q · filed 2019-05-09 | $547.87K derived: sum of 2 quarters · filed 2019-05-09 | $812.11K derived: sum of 3 quarters · filed 2019-05-09 | $1.07M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $305.04K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $569.29K derived: sum of 2 quarters · filed 2019-03-18 | $825.03K derived: sum of 3 quarters · filed 2019-03-18 | $1.16M 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $264.25K 10-Q · filed 2018-11-13 | $519.99K derived: sum of 2 quarters · filed 2018-11-13 | $852.21K 10-Q · filed 2018-11-13 | $1.11M derived: sum of 4 quarters · filed 2018-11-13 | ||||
| 2017-06-30 | $255.74K 10-Q · filed 2018-08-09 | $587.96K 10-Q · filed 2018-08-09 | $843.66K derived: sum of 3 quarters · filed 2018-08-09 | $1.13M derived: sum of 4 quarters · filed 2018-08-09 | ||||
| 2017-03-31 | $332.22K 10-Q · filed 2018-05-11 | $587.92K derived: sum of 2 quarters · filed 2018-05-11 | $875.69K derived: sum of 3 quarters · filed 2018-05-11 | $1.09M derived: sum of 4 quarters · filed 2018-05-11 | ||||
| 2016-12-31 | $255.70K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $543.47K derived: sum of 2 quarters · filed 2018-04-02 | $757.58K derived: sum of 3 quarters · filed 2018-04-02 | $1.69M 10-K · filed 2018-04-02 | ||||
| 2016-09-30 | $287.77K 10-Q · filed 2017-11-07 | $501.89K derived: sum of 2 quarters · filed 2017-11-07 | $1.44M 10-Q · filed 2017-11-07 | $1.51M derived: sum of 4 quarters · filed 2018-04-02 | ||||
| 2016-06-30 | $214.11K 10-Q · filed 2017-08-14 | $1.15M 10-Q · filed 2017-08-14 | $1.22M derived: sum of 3 quarters · filed 2018-04-02 | $1.25M derived: sum of 4 quarters · filed 2018-04-02 | ||||
| 2016-03-31 | $937.31K 10-Q · filed 2017-05-09 | $1.01M derived: sum of 2 quarters · filed 2018-04-02 | $1.04M derived: sum of 3 quarters · filed 2018-04-02 | $1.28M derived: sum of 4 quarters · filed 2018-04-02 | ||||
| 2015-12-31 | $73.52K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $102.53K derived: sum of 2 quarters · filed 2018-04-02 | $344.56K derived: sum of 3 quarters · filed 2018-04-02 | $394.75K 10-K · filed 2018-04-02 | ||||
| 2015-09-30 | $29.02K 10-Q · filed 2016-11-08 | $271.04K derived: sum of 2 quarters · filed 2016-11-08 | $321.23K 10-Q · filed 2016-11-08 | $489.81K derived: sum of 4 quarters · filed 2016-11-08 | ||||
| 2015-06-30 | $242.03K 10-Q · filed 2016-08-15 | $292.21K 10-Q · filed 2016-08-15 | $460.80K derived: sum of 3 quarters · filed 2016-08-15 | |||||
| 2015-03-31 | $50.19K 10-Q · filed 2016-05-16 | $218.77K derived: sum of 2 quarters · filed 2016-05-16 | ||||||
| 2014-12-31 | $168.59K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-23 | $1.09M 10-K · filed 2016-03-23 | ||||||
| 2014-09-30 | $918.00K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |